4.2 COMMITTEE REPORTS OPEN FOR DISCUSSION Call 44 20 7399 2760 AUDIT or E-mail: investors@hikma.
com LETTER FROM THE CHAIRMAN Dear Shareholder I would like to give you an overview of the operation and scope of the Audit Committee and report on its work over the past year.
The membership of the Audit Committee has not changed during the year, it comprised Sir David Rowe-Ham, Michael Ashton, Ronald Goode, Robert Pickering and myself.
The Committees written terms of reference are available on Hikmas website.
The Committee met ten times during the year.
We invited the Chief Financial officer, Auditors, Internal Auditors and certain members of the finance team to attend meetings as required.
As in previous years, the Committee met with the internal and external auditors without management present.
The Committee has an annual cycle of work relating to reviewing financial performance and forecasting, results announcements, AUDIT REPORT internalcontrol, risk management and internal and external audit.
72 Letter from the Chairman The finance department has continued to provide first rate reporting, whilst working on the complex integration of our 73 Our Highlights acquisitions and the development and output of management 73 Membership and attendance reporting systems.
73 Responsibilities As an organization Hikma is committed to clear and open 73 Terms of reference communication.
As I mentioned last year, I remain open to discussion 74 Risk with shareholders should they have any concerns that they wish to raise 74 Internal Audit directly with me.
75 Internal Control 75 External Audit Breffni Byrne Chairman of the Audit Committee 72 HIKMA PHARMACEUTICALS PLC ANNUAL REPORT 2012
